Tempest Therapeutics, Inc. - FORM 10-K - EX-32.1 - March 16, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Tempest Therapeutics, Inc.Financial_Report.xls
EX-32.2 - EX-32.2 - Tempest Therapeutics, Inc.a2223498zex-32_2.htm
EX-21.1 - EX-21.1 - Tempest Therapeutics, Inc.a2223498zex-21_1.htm
EX-10.7 - EX-10.7 - Tempest Therapeutics, Inc.a2223498zex-10_7.htm
EX-31.2 - EX-31.2 - Tempest Therapeutics, Inc.a2223498zex-31_2.htm
EX-31.1 - EX-31.1 - Tempest Therapeutics, Inc.a2223498zex-31_1.htm
EX-10.6 - EX-10.6 - Tempest Therapeutics, Inc.a2223498zex-10_6.htm
EX-23.1 - EX-23.1 - Tempest Therapeutics, Inc.a2223498zex-23_1.htm
EX-10.33 - EX-10.33 - Tempest Therapeutics, Inc.a2223498zex-10_33.htm
EX-10.32 - EX-10.32 - Tempest Therapeutics, Inc.a2223498zex-10_32.htm
EX-10.24 - EX-10.24 - Tempest Therapeutics, Inc.a2223498zex-10_24.htm
EX-10.23 - EX-10.23 - Tempest Therapeutics, Inc.a2223498zex-10_23.htm
EX-10.21 - EX-10.21 - Tempest Therapeutics, Inc.a2223498zex-10_21.htm
EX-10.22 - EX-10.22 - Tempest Therapeutics, Inc.a2223498zex-10_22.htm
EX-10.34 - EX-10.34 - Tempest Therapeutics, Inc.a2223498zex-10_34.htm
10-K - 10-K - Tempest Therapeutics, Inc.a2223498z10-k.htm

QuickLinks -- Click here to rapidly navigate through this document


EXHIBIT 32.1

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer

        In connection with the Annual Report on Form 10-K of OvaScience, Inc. (the "Company") for the period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Michelle Dipp, M.D., Ph.D., as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

            (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

            (2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 16, 2015

  By:   /s/ MICHELLE DIPP
 Michelle Dipp, M.D., Ph.D.
 Chief Executive Officer
(Principal executive officer)



QuickLinks

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer

Tempest Therapeutics, Inc. Reports